Assistant Professor, Medicine, University of Washington School of Medicine
Oncology
Dr. Damian J. Green, MD
Damian J. Green is an expert in the field of Oncology. He attended The Ohio State University College of Medicine. Doctor Damian J. Green, MD is a published doctor. He has 26 papers published. The most current publication "Anti-CD45 radioimmunotherapy without TBI before BMT facilitates persistent haploidentical donor engraftment in a murine model." He accepts all Medicare patients.
Publications
- Anti-CD45 radioimmunotherapy without TBI before BMT facilitates persistent haploidentical donor enGraftment in a murine model.
- Maintenance rituximab after autologous stem Cell transplantation in patients with mantle Cell lymphoma.
- Long-Term Outcomes of Patients with Persistent Indolent B-Cell Malignancies Undergoing Nonmyeloablative Allogeneic Transplantation.
- Panobinostat: a review of trial results and future prospects in multiple Myeloma.
- In Vivo Localization of 90Y and 177Lu Radioimmunoconjugates Using Cerenkov Luminescence Imaging in a Disseminated Murine Leukemia Model.
- Brentuximab vedotin administered to platinum-refractory, transplant-naïve Hodgkin Lymphoma patients can increase the proportion achieving FDG PET negative status.
- Autologous transplant for relapsed follicular Lymphoma: impact of pre-transplant rituximab sensitivity.
- Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR™ therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent l...
- Radiolabeled Anti-CD45 Antibody with Reduced-Intensity Conditioning and Allogeneic Transplantation for Younger Patients with Advanced Acute Myeloid Leukemia or Myelody...
- A Preclinical Model of CD38-Pretargeted Radioimmunotherapy for Plasma Cell Malignancies.
- A prospective study of lenalidomide monotherapy for relapse after Allo-SCT for multiple Myeloma.
- Specific Features Identify Patients with Relapsed or Refractory Mantle Cell Lymphoma Benefitting from Autologous Hematopoietic Cell Transplantation.
- Anti-CD45 radioimmunotherapy using 211At with bone marrow transplantation prolongs survival in a disseminated murine Leukemia model.
- Pretargeted Radioimmunotherapy using Genetically Engineered Antibody-Streptavidin Fusion Proteins for Treatment of Non-Hodgkin Lymphoma.
- Mantle Cell Lymphoma International Prognostic Index but Not Pretransplantation Induction Regimen Predicts Survival for Patients With Mantle-Cell Lymphoma Receiving Hig...
- Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid Leukemia xenograft model.
- Pulmonary Embolization of Fat and Bone Marrow in Cynomolgus Macaques (Macaca fascicularis).
- Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin Lymphomas expressing CD20: a preclinical model toward optimal consoli...
- Pretargeting CD45 enhances the selective delivery of radiation to hematolymphoid tissues in nonhuman primates.
- A comparative analysis of conventional and pretargeted radioimmunotherapy of B-Cell lymphomas by targeting CD20, CD22, and HLA-DR singly and in combinations.
- Extracorporeal adsorption therapy: a method to improve targeted radiation delivered by radiometal-labeled monoclonal antibodies.
- Pretargeted radioimmunotherapy for B-Cell lymphomas.
- Comparative Efficacy of 177Lu and 90Y for Anti-CD20 Pretargeted Radioimmunotherapy in Murine Lymphoma Xenograft Models.
- Anti-CD45 Radioimmunotherapy with 90Y but Not 177Lu Is Effective Treatment in a Syngeneic Murine Leukemia Model.
- Pretransplant minimal residual disease predicts survival in mantle Cell lymphoma patients undergoing autologous stem Cell transplantation in complete remission.
Schools
Ohio State University College of Medicine
Oh State University Hospital
Procedures Preformed
- HPC Transplantation (Stem Cell Transplant)
Conditions Treated
- Acute Leukemia
- Anemia
- Basal Cell Carcinoma
- Breast Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Education
-
University of Washington -
Ohio State University Hospital -
The Ohio State University College of Medicine
Drug Facts
| NPI NUMBER | 1801002076 | |
| NPPES Provider LastName | GREEN | |
| NPPES Provider FirstName | DAMIAN | |
| NPPES Provider ZIPCode | 981094405 | |
| NPPES Provider State | WA | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 138.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1801002076 |
| Last Name Of The Provider | GREEN |
| First Name Of The Provider | DAMIAN |
| View All |
Similar Doctors
|
Dr. Anthony L. Back, MD
 This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Bernardo H. Goulart, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Julie R. Gralow, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Heather H. Cheng, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Evan Y. Yu, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Daniel Y. Wu, MD
This Doctor is OpenDoctor Recommended.
|